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A B S T R A C T
Trans-plasma membrane electron transfer (tMPET) is a process by which reducing equivalents, either electrons
or reductants like ascorbic acid, are exported to the extracellular environment by the cell. TPMET is involved in a
number of physiological process and has been hypothesised to play a role in the redox regulation of cancer
metabolism. Here, we use a new electrochemical assay to elucidate the ‘preference’ of cancer cells for different
trans tPMET systems. This aids in proving a biochemical framework for the understanding of tPMET role, and for
the development of novel tPMET-targeting therapeutics. We have delineated the mechanism of tPMET in 3 lung
cancer cell models to show that the external electron transfer is orchestrated by ascorbate mediated shuttling via
tPMET. In addition, the cells employ a different, non-shuttling-based mechanism based on direct electron
transfer via Dcytb. Results from our investigations indicate that tPMETs are used differently, depending on the
cell type. The data generated indicates that tPMETs may play a fundamental role in facilitation of energy re-
programming in malignant cells, whereby tPMETs are utilised to supply the necessary energy requirement when
mitochondrial stress occurs. Our findings instruct a deeper understanding of tPMET systems, and show how
different cancer cells may preferentially use distinguishable tPMET systems for cellular electron transfer pro-
cesses.
1. Introduction
Trans-plasma membrane electron transport systems (tPMETs)
transport electrons across the cell plasma membrane. These systems are
expressed in cells across all forms of life [1]. They are understood to be
involved in a range of physiological processes [2], including protection
from external oxidants [3,4], defence against infection [5,6], the
maintenance of intracellular redox state [7], iron reduction [8–10],
sperm maturation and fertilisation [11–13], and platelet activation
[14–16]. TPMET is further hypothesised to play a role in cancer energy
metabolism [17–19]. Otto Warburg first suggested the reprogramming
of energy metabolism to a state of aerobic glycolysis as a fundamental
change of the cancer cell phenotype [20]. This reprogramming of en-
ergy metabolism is now thought of as a hallmark of cancer [21,22]. One
result of a preferential use of aerobic glycolysis would be an increase in
reduced nicotinamide adenine dinucleotide (NADH), due to less oxi-
dative phosphorylation to convert NADH to NAD+. TPMET may play a
role in cancer biogenesis by maximising the levels of NAD+ regenera-
tion, and this would allow the facilitation of greater metabolic flux via
glycolysis, thereby alleviating cellular stress [3,17,18,23,24]. The
pentose phosphate pathway is also upregulated in cancer [25], which is
linked to tPMET through nicotinamide adenine dinucleotide phosphate
(NADPH) electron donation, and ascorbate regeneration using glu-
tathione (GSH) and NAD(P)H [26]. It is important to note that this role
is not fully elucidated, and more studies are required to investigate this
further.
In the intestinal and pulmonary epithelium tPMET has been re-
ported to be involved in the transport of metals [8,27]. The mechanisms
of this apical membrane electron transport in the lung and intestine are
thought to be similar, and can occur via an enzyme mediated process, of
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which duodenal cytochrome b561 (Dcytb) has been suggested as a
mediator [9], or alternatively via a cross membrane ascorbic acid (vi-
tamin C, ascorbate) shuttle system. Both systems reduce apical ferric
iron to ferrous iron, thus enabling its transport across plasma mem-
brane via transporters such as the divalent metal transporter 1 [27,28]
(DMT1). The ascorbate shuttling mechanism of tPMET has been shown
to occur in K562 leukaemia cells [29], skeletal muscle cells [30], as-
trocytes [31], monocytes [32], and Caco-2 cells [33]. There is also a
substantial body of research into solely ascorbate shuttling – not in-
volving the reduction of an external electron acceptor - in human cells,
including in astrocytes [34,35], endothelial cells [36,37], hepatocytes
[38], and neuroblastoma cells [39]. Some research has also been con-
ducted into the release of ascorbate and its presence the lung in guinea
pigs, rats, and in human lung lavage [40–42]. It has also been reported
that Iron uptake by human bronchial epithelial cells uses tPMET that
can involve Dcytb [9].
Studying tPMET systems is important as they are currently im-
plicated as a potential targets to inducing anti-proliferative effect in
cells in vitro [19,43]. The research reported by Grasso et al. [19] and
Prata et al. [43] used ubiquinone-based compounds targeting tPMET to
produce anti-leukemic activity, in combination with intracellular redox
disruption. Ruthenium-based compounds have also been investigated
for similar purpose [44], whilst cancer therapy using pharmacological
doses of ascorbate is a rapidly growing approach [45–49].
The presence of cell-surface oxidoreductase systems is well known
[50], and there is mounting evidence that tPMET systems can facilitate
the re-oxidation of intracellular NAD(P)H, in response to decreased
mitochondrial activity, in various cell types [7,17,18,51]. Where the
current understanding will benefit is the integration of how both shuttle
and enzyme-based tPMET systems are used in tandem, and the differ-
ences in their utilisation between different cell types. This would mean
that efforts to target tPMET activity in cancer need to consider the
differences in the use of these systems by different cancer cell types, if
tPMET is to be used as a target for cancer therapy.
Recent work in vivo has suggested that cancer cells reduce ascorbate
levels to increase expression of the hypoxia-induced factor 1 (HIF1), but
still maintain levels of ascorbate at 60–70% of ‘normal’ physiological
level [52]. It was also suggested that this is due to a higher turnover of
ascorbate in tumorigenic cells [47].
We focus our work on cells of epithelial origin from the lung, as
previous work found that iron-related tPMET systems are active in the
lung and intestine epithelial tissues. This would mean that in these cells
the necessary mechanisms for tPMET regeneration of intracellular
redox couples are already present and active. The activity is primarily
attributed to exposure to high levels of catalytically active iron and the
need for its detoxification [8].
Regeneration of ascorbate from either dehydroascorbate (DHA) or
the ascorbate free radical (AFR) can occur in several ways [26]. Re-
duction of dehydroascorbate (DHA) to ascorbate can be facilitated in-
side of the cytosol by direct non-enzymatic reduction via glutathione
[53]; by the NADPH-dependant enzymes thioredoxin reductase [54] or
3-alpha-Hydroxysteroid dehydrogenase [55]; or through the glutha-
thione-dependant enzymes glutaredoxin [56], protein sulphide dis-
omerase [56] and omega class glutathione transferase [57]. The free
radical of ascorbate (AFR), can be reduced to ascorbate either in the cell
via NADPH-dependant thioredoxin reductase [58] or NADH-dependant
cytochrome b5 reductase [59], and can be regenerated extracellularly
via a cell surface NADH:AFR reductase [60]. Since DHA and the AFR are
reduced using mechanisms utilising NAD(P)H and glutathione (GSH),
this forms an interplay with the glycolytic and pentose pathways of the
cell.
In this work we aim to delineate the biochemical systems that occur
in tPMET in selected malignant lung epithelium. The work expands on
current knowledge on interplay of different tPMET processes, the po-
tential role of tPMET in cancer, and the ability of varying cell types to
use differing mechanisms to achieve tPMET. The work builds on our
recent report on differences in electrical charge flux that exist in dif-
ferent types of epithelial cancer cells originating from the lung tissue
[61].
We used a newly developed electrochemical method [61] – in cor-
roboration with lactate spent medium analysis to establish basal level
tPMET activity in the cancer cell models. In combination with chemical
inhibitor and knock down studies two tPMET systems were identified.
One charge transfer mechanism occurred via an ascorbate shuttle
tPMET. The second was via a Dcytb redox protein based tPMET. We also
provide evidence based on cell metabolism, viability and mitochondrial
function that tPMET activity could be linked to energy reprogramming
of cancer cells.
2. Methods
2.1. Materials
All materials were supplied by Sigma Aldrich Ltd., unless otherwise
stated.
2.2. Cell culture
The three cell lines tested in this study were Calu-3, H1299, and
A549. Calu-3 cells (ATCC® HTB-55) are a human lung adenocarcinoma
derived from a pleural effusion metastatic site of the bronchial lung
epithelium, and of epithelial type. H1299 cells (ATCC® CRL-5803™) are
non-small cell human lung adenocarcinoma cells derived from a lymph
node metastatic site of the lung, and of epithelial type. A549 cells are
non-small cell adenocarcinomic human alveolar (type II) basal epithe-
lial cells, and are commonly used as an alveolar type II model. All cell
lines were purchased from American Type Culture Collection
(ATCC).The passage numbers for all the experiments were between 32
and 37 for Calu-3 cells, 10–21 for H1299 cells, and 11–24 for A549
cells. Any detachment of cells was performed by 0.5mL 0.25% trypsin/
EDTA (with phenol red). All cells were grown in DMEM (Dulbecco's
Modified Eagles Medium) containing high glucose supplemented with
10% v/v FBS (fetal bovine serum), 100 U/mL penicillin, 100 μg/mL
streptomycin, and 24mM HEPES (N-(2-hydroxyethyl) piperazine-N′-(2-
ethanesulfonic acid)) buffer at 37 °C, 5% CO2. For all experiments Calu-
3 cells were harvested after 4 days, and A549 and H1299 cells following
3 days of growth. This ensured all three cell lines were in an exponential
growth phase when used in experiments, as described previously [61].
All cells were harvested at a confluency of ∼90%. Unless otherwise
stated, following the growth period the medium was aspirated, and
cells washed three times with warm phosphate buffered saline (PBS).
All cell assays were performed at 37 °C and with supplemented media
unless otherwise stated. For all experiments performed in a 6 well
format wells contained, g 6.3×105 cells/well for Calu-3 cells, and
2.5×105 cells/well for A549 and H1299 cells, unless described
otherwise. Cell counting and trypan blue exclusion assays were per-
formed on all cell assays.
2.3. Electrochemical analysis
A three-electrode system comprising a 33 μm carbon fibre working
microdisk electrode, a saturated calomel reference electrode, and a
platinum wire counter electrode was used for all electrochemical ana-
lysis (ALS Co. Ltd., Japan). An Autolab PGStat302A potentiostat with
low current detection module (ECD) (Metrohm Autolab, Utrecht,
Netherlands) and NOVA 2.1 software was used in all experiments.
Linear sweep voltammetry was performed with solutions containing
differing ratios of oxidised and reduced forms of iron (as above) and
were carried out by scanning from 650 to −150mV, at a scan rate of
10mV s−1. A current range of 100 pA was used for all experiments,
with a low current module employed for all experiments. All electro-
chemistry was recorded with a HBSS only sample acting as a control to
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allow for baseline subtraction. Between each solution tested, the mi-
croelectrode was polished for 4min using a PK-3 electrode polishing kit
(ALS Co. Ltd., Japan). Pseudo steady-state values were determined by
assessing a first derivative function of the voltammogram and cross-
referencing with the original curve to clarify that this was the voltage
where the pseudo steady state was located.
2.4. Ascorbic acid ‘loading’ and determination of intracellular ascorbic acid
concentrations
Calu-3 cells were added to give 2.5×104, and H1299 and A549 at
1.0×104 cells per well in 2mL of DMEM in a 12 well plate. The cells
were incubated for 30min with either 0, 250, 500, 750 or 1000 μM
dehydroascorbic acid (DHA) in phosphate buffered saline (PBS, 0.01M,
pH 7) for 30min. Determination of intracellular ascorbic acid con-
centration was conducted according to a the ferrocyanide determina-
tion assay of Lane and Lawen [62]. After incubation, the solution was
aspirated, and the cells washed three times in warm (37 °C) PBS. Cell
suspensions were centrifuged at 250×g for 5min, re-suspended in ice-
cold PBS, and then centrifuged for the second time at 250×g for 5min.
Aspiration of the PBS resulted in cellular pellet. The cell pellet was re-
suspended in 0.1% (w/v) saponin solution in ice-cold PBS and agitated
on ice for 10min to ensure thorough cellular lysis. Cellular debris was
removed by centrifugation of the crude lysate at 16,000×g for 5min in
a refrigerated microcentrifuge (4 °C). 100 μL aliquots from each sample
were added to wells in a 96-well flat bottom plate that contained either
25 μL/well of PBS without L-ascorbate-oxidase (AO) or 25 μL/well of
45.5 U/mL stock solution of AO in PBS. A set of standards of 0, 2.5, 5,
10, 15 and 20 μm of L-ascorbic acid were also prepared and added to
wells with or without AO, as above. The 96 well plate was left at room
temperature for 5min in the dark, followed by the addition of 3.5mM
potassium ferricyanide (FIC) in PBS to all wells. The plate was further
incubated at room temperature in the dark for 5min, before the addi-
tion of 25 μL of a freshly constructed solution containing 50% (v/v)
acetic acid and 30% (w/v) trichloroacetic acid (TCA) to all wells. Im-
mediately afterwards the following solutions were added to all wells:
100 μL of a ferrocyanide (FOC) determination solution containing 2mL
of 3M Na-acetate (pH 6.0), 0.5mL of glacial acetic acid (~17.4M acetic
acid), 2 mL of 0.2M citric acid, 2mL of 3.3mM FeCl3 in 0.1M acetic
acid, and 1mL of 30mM ferene-S. The plate was incubated for 30min
in the dark at room temperature. Absorbance was read at 593 nm using
a Tecan plate reader (Spark 10M, Tecan Ltd). The amount of in-
tracellular ascorbate as nmole ascorbate per cell was calculated by in-
itially subtracting the absorbance values at λ593 nm for the ‘+ AO’ wells
from the corresponding ‘- AO’ wells for each of the standard samples,
and plotting a standard curve of the known concentration against the
λ593 nm. The difference between AO positive ‘+AO’ and AO negative
‘-AO’ wells was plotted for each of the cellular samples, and the
quantity of ascorbate obtained interpolated from the standard curve.
This experiment was carried out with two technical repeats and four
biological repeats.
2.5. MTS cell assay
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H tetrazolium) assay (CellTiter 96,
Promega) in 96-well plate format was used to test the mitochondrial
metabolic activity of the cells incubated with DHA (ascorbic acid
‘loaded’). Cells were added to give 8.4×103 cells per well for A549,
and H1299, and 2.1× 104 cells per well for Calu-3 cells in 150 μL of
DMEM in 96 well-plate. The cells were incubated with 0, 100, 200, 300,
400, 500, 600, 700, 800, 900 and 1000 μM of DHA in PBS for 30min.
Following incubation, cells were washed once with warm PBS and in-
cubated with 20.0 μL of MTS reagent in 100 μL of DMEM (without
antibiotics) per well for 2 h). Blank subtractions consisted of DMEM
without antibiotics. Relative metabolic activity was calculated by
setting the absorbance, measured at λ490 nm for the untreated cell
control as 100%, and the positive control (0.2% v/v Triton X-100 so-
lution) was assumed to result in total cell lysis and set at 0%. This ex-
periment was carried out with three technical repeats and three bio-
logical repeats.
2.6. Inhibition of GLUT1-mediated DHA uptake
A549 and H1299 cells were added to give 0.10×106 cells/well,
and Calu-3 cells at 0.25×106 cells/well in 12 well plates. The cells
were incubated with either 0 μM DHA solution,750 μM DHA solution,
or 750 μM DHA and 50 μM cytochalasin B (CB) solution, all prepared in
PBS for 30min. Following the incubation intracellular ascorbic acid
levels were determined by Lane and Lawen [62] assay as described
above. This experiment was carried out with two technical repeats and
three biological repeats.
2.7. Bicinchoninic acid assay
Following the removal of the cell incubation medium for electro-
chemical analysis of cell conditioned samples, wells were washed three
times with PBS by gentle swirling for 5min. 1.0mL of 2% Triton X-100
solution in PBS buffer was then added to each well and the plates in-
cubated 20min. The lysed cell samples were then transferred to a
micro-centrifuge tube and centrifuged at 16000×g for 20min. The
supernatant was removed and transferred to a fresh micro-centrifuge
tube before analysis using a Pierce™ BCA Protein Assay Kit
(ThermoFisher Scientific Ltd) using the manufacture's recommended
protocol.
2.8. Anion channel inhibition
The cells for all three cell lines were added to a 6 well plate. To
supplement (‘load’) cells with ascorbic acid, the cells were incubated
with 750 μM dehydroascorbic acid (DHA) solution in PBS for 30min at
37 °C. DHA solution was aspirated, the cells washed with PBS, and then
incubated with 0 or 500 μM 4,4′-diisothiocyano-2,2′-stilbenedisulfonic
acid (DIDS) in DMEM (no antibiotics), for 20min. DIDS solution was
aspirated and the cells washed with PBS. The cells were then incubated
with HBSS for 45min. An electrochemical assay was then performed as
described above, with some modifications. In this instance 1.0mL ali-
quots were taken from two wells, one with and one without DIDS, for
electrochemical analysis. Electrochemical analysis was carried out as
described under the ‘electrochemical analysis' section, with con-
comitant bicinchoninic acid assay for protein quantification, also as
described above. In a separate experiment the viability of the cells
following this assay procedure was tested. The same protocol was fol-
lowed until electrochemical analysis step, whereby instead of electro-
chemical analysis the cells were detached using EDTA. This experiment
was carried out with one technical repeat, and five biological repeats.
Inhibition was carried out with two further inhibitors. The experi-
ment was carried out as described in this section, with some mod-
ifications. Following seeding, culture and DHA incubation and removal
(all as described above), the cells were incubated with 0 or 500 μM
Disodium 4-acetamido-4′-isothiocyanato-stilben-2,2′-disulfonate (SITS)
or 100 μM 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB) in
DMEM not supplemented with FBS for 20min. The inhibitor solution
was aspirated and the cells washed. The cells were then incubated in
HBSS for 45min prior to the removal of 1mL of supernatant.
Electrochemical analysis was carried out on the supernatant as pre-
viously described in the ‘electrochemical analysis’ section. A con-
comitant bicinchoninic acid assay for protein quantification as de-
scribed. This experiment with NPPB and SITS was carried out with
three technical repeats and three biological repeats.
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2.9. tPMET activity in cells not loaded with ascorbic acid
The cells were added to a 6 well plate. Either HBSS or 0.1mM
ferrocyanide (FIC) in HBSS was added. Following two hours incubation,
1.0 mL of culture medium was removed and tested electrochemically, as
described in the electrochemical analysis method section. This experi-
ment was carried out with three technical repeats and three biological
repeats.
2.10. Metabolomics analysis of cell culture medium
The cells were added in 6 well plate. Cells were washed in PBS
buffer and either DMEM, HBSS, 0.01mM FIC in HBSS, or 0.1mM FIC in
HBSS was added to the wells and cells incubated for 2 h at 37 °C. 300 μL
of DMEM was then removed and centrifuged at 3000×g for 5min.
250 μL of the supernatant was transferred to a fresh tube containing
750 μL of pre-cooled (−20 °C) methanol. The solution was vortexed for
1min to precipitate proteins. The precipitate and supernatant samples
were then incubated at −20 °C for 20min prior to vortexing for 15 s,
and subsequent centrifugation at 12000×g for 10min at 4 °C. The
supernatant was collected and stored at −80 °C.
Preparation of the samples for metabolomics analysis consisted of
placing 100 μL of each sample into pre-labelled auto-sampling tubes
with 200 μL glass inserts. A quality control (QC) sample was also pre-
pared containing an equal portion of all samples tested for instrument
performance assessment [63]. Mass spectrometry analysis was carried
out using an Orbitrap mass spectrometer (Thermo Exactive) in combi-
nation with liquid chromatography (LC) (Thermo Accela) from Thermo
Scientific (Thermo Fisher Scientific, Hemel Hempstead, UK). It was
operated with electrospray ionization (ESI) running in the negative
(ESI-) and positive (ESI+) modes. The voltages used for the experiment
were: spray voltage, 4500 V (ESI+) and 3500 V (ESI-), capillary voltage
at 40 V (ESI+) and 30 V (ESI-), tube lens voltage at 70 V for both (ESI
+) and (ESI-), skimmer voltage at 20 V (ESI+) and 18 V (ESI-). Sheath
gas 40, desolvation gas 5, and sweep gas 1. The temperature for this
experiment was maintained at 275 °C and 150 °C for capillary and
probe, respectively. Mass calibration was carried out for both positive
and negative mode before the analysis of each patch. The mass range
was up to 1400m/z for positive and negative modes, and the run time
was 24 mins for each sample. To separate the components chromato-
graphically a ZIC-pHILIC (4.6× 150mm and 5 μm particle size, Merck
Sequant) was used. The mobile phase was composed of 20mM am-
monium carbonate in water (solvent A) and 100% acetonitrile (solvent
B). Metabolites were separated according to a linear gradient as fol-
lowing: 0–15min, 20% A, 15–17min, 95% A, 17–24min, 20% A at
300 μL/min flow rate and the injection volume of 10 μl. and the tem-
perature of the column was kept at 45 °C.
To process raw data obtained from LC-MS, XCMS [64] and mzMatch
[65] were used for untargeted peak-picking and peak matching, re-
spectively. IDEOM was performed for putative metabolite identification
and noise filtering based on default parameters [66]. Metabolite iden-
tification considered two levels of identification; level 1 (L1) identifi-
cation according to the metabolomics standards initiative by matching
retention times and accurate masses of authentic standards, and level 2
(L2) identification when the predicted retention times were employed
as the standards were not available [67]. Pre-processed data were
analysed statistically by performing multivariate and univariate ana-
lysis. Orthogonal partial least squares-discriminant analysis (OPLS-DA)
was carried out by SIMCA-P v13.0.2 (Umetrics, Umea, Sweden) as a
supervised multivariate model. This multivariate analysis was used as
the first step for separation data into classes and evaluate the metabolic
changes in HBSS, 0.01 FIC in HBSS or 0.1mM FIC in HBSS treated cells
for each cell line (Calu-3, A549 and H1299 cells). OPLS-DA was vali-
dated by the multiple correlation coefficient (R2), and further cross-
validated R2 (Q2) which is the predictability of the model. The key mass
ions representing potential biomarkers were determined based on
Variable Importance in Projection (VIP) values obtained from two-way
orthogonal comparisons. Mass ions with VIP values greater than one
were considered as discriminant biomarkers. Univariate analysis was
performed in parallel to multivariate analysis. t-test with false discovery
rate (FDR) correction was performed using Metaboanalyst to find the
significantly changed mass ions between HBSS, 0.01 FIC in HBSS or
0.1 mM FIC in HBSS treated cells for each cell line (Calu-3, A549 and
H1299 cells). Mass ions with FDR < 0.05 and VIP > 1 were con-
sidered as statistically significant. MetaboAnalayst is a web server that
afford metabolomic data analysis, interpretation and visualisation
Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used
to analyse and visualize the affected pathway. This experiment was
carried out with one technical repeats and six biological repeats.
2.11. Extracellular ascorbic acid as a component of tPMET
The cells were loaded with ascorbic acid, as described above, and
then incubated in either HBSS, 0.1 mM FIC in HBSS, HBSS containing
10 U/mL AO, or HBSS containing 0.1mM FIC and 10 U/mL AO, in
triplicate. Following two hours incubation, 1.0mL of cell medium was
removed, and tested electrochemically, as described above. Values for
‘HBSS samples’ were subtracted from ‘FIC samples’ to remove any
current contribution from the buffer in the voltammograms.
An electrochemical assay was performed in either HBSS, or 0.1 mM
FIC in HBSS, in triplicate. An additional plate contained either HBSS
+10 U/mL AO, or 0.1 mM FIC+10 U/mL AO added to the cells, in
triplicate. Following two hours incubation, 1mL of supernatant was
removed, and tested electrochemically, as described above. HBSS in-
cubated samples were subtracted from FIC samples to remove any
current contribution from the buffer. The experiment was carried out in
three technical repeats and four biological repeats.
2.12. Live cell immunofluorescence imaging
Cells were seeded in 24 well plates onto poly-L-lysine coated cov-
erslips at 1.25×105 per well for Calu-3 cells, or 5× 104 for H1299 and
A549 cells and incubated for 24 h. The well plate was transferred onto
ice for the duration of the experiment. Following each staining step the
wells were washed three times by 5min swirling with ice-cold PBS.
Non-specific binding was blocked by incubation in 1.0% PBA (1% bo-
vine serum albumin in PBS) for 30min (500 μL). The plate was gently
rocked during incubation. Primary antibody staining was carried out
with anti-cytochrome b reductase 1 antibody (ab66048, Abcam Ltd) at
10 μg/mL in 1% PBA for 1 h. Secondary staining with donkey anti-
rabbit IgG (H+ L) Highly Cross-Adsorbed, Alexa Fluor® 647
(ThermoFisher Scientific Ltd., A31573) was carried out at 2 μg/mL for
45min in the dark. Following secondary antibody staining, two drops of
NucBlue™ Live ReadyProbes™ Reagent (ThermoFisher Scientific Ltd)
was added to all wells.
Imaging of live cell samples was carried out using Zeiss PS1 Super
Resolution Microscope with a 63× water lens. The far red channel
(633 nm laser line) for Dcytb staining (displayed as red) used a gain of
750 and a laser power of 10%, whilst the blue channel (488 nm laser
line) used a gain of 800 and a laser power of 4%. Z-stack slice and 3D
images were analysed using Zen Black (Zen Software Ltd). Images were
taken of multiple areas to confirm staining was representative of the
cell population.
2.13. Transfection protocol
Pre-constructed plasmids were ordered from SigmaAldrich Ltd.
Control plasmid: MISSION® pLKO.1-puro TurboGFP™ shRNA Control
Plasmid DNA (SHC004); knockdown plasmids (hereby referred to as
shRNA1 and shRNA2) were: CYBRD1 MISSION® shRNA Plasmid DNA
cytochrome b reductase 1 (Human, SHCLND-NM_024843), shRNA1:
TRCN0000236452, shRNA2: TRCN0000236455. Cells were transfected
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following the manufacturer's protocol for Lipofectamine™ 3000 reagent
(ThermoFisher Scientific Ltd). Cells were grown for one day for A549
and H1299 cells, or two days for Calu-3 cells, and were transfected with
the appropriate plasmids using Lipofectamine 3000 and Gibco™ Opti-
MEM™ Reduced Serum Media (ThermoFisher Scientific Ltd) as the
transfection medium. The cells were then cultured for a further two
days without removal of medium prior to any further experimental
work. To determine transfection efficiency the cells were seeded in 24
well plates at 1.25× 105 for Calu-3 cells, or 5×104 for H1299 and
A549 cells, in 1mL of DMEM, and transfected according to the protocol
outlined above. A non-transfected control was also grown. Following
completion of the growth period, cells were harvested using 250 μL
accutase per well. Once detached 250 μL of DMEM was added to each
well to stop the action of the accutase, and the cells were pelleted via
centrifugation at 300 g for 5min. The resulting pellet was washed in
phosphate buffered saline (PBS) and then samples were tested for
transfection efficiency (green channel fluorescence) using a flow cyt-
ometer. All flow cytometry was carried out in collaboration with The
University of Nottingham Flow Cytometry Facility, using a FC500
Series Flow Cytometer (Backman Coulter Ltd). All analysis was carried
out using Kaluza, Analysis Version 1.5. Please note due to minimal
transfection efficiency for the Calu-3 cells, only A549 and H1299 cells
were assayed further. This experiment was carried out with two tech-
nical repeats and three biological repeats.
2.14. RT-qPCR for CYBRD1 knockdown
H1299 and A549 cells were seeded in 6 well plates at 2.5× 105/
well and grown for 24 h, and transfected according to the above section.
The cells were washed with 1mL PBS prior to harvesting by the addi-
tion of 0.5 mL accutase until detachment. 0.5mL warm DMEM was
added, and the cells pelleted by centrifugation at 300 g for 5min. The
resulting pellet was washed using warm PBS and centrifugation, as
described above. On ice, the pellet was lysed and RNA extraction was
carried out in line with the manufacturer's protocol for RNeasy mini kit
(Qiagen Ltd., Cat No./ID: 74104). Following RNA extraction, the pur-
ified RNA was tested for RNA content using a NanoDrop 1000
Spectrophotometer (ThermoFisher Scientific Ltd). cDNA was prepared
via reverse transcription as outlined in the Quantiscript Reverse
Transcriptase kit (Qiagen Ltd., Cat No./ID: 205311). Quantitative
polymerase chain reaction (qPCR) was used to amplify the prepared
cDNA using primers designed using Roche ProbeFinder, and then
checked for veracity using USCS In-silico PCR software. Primers for
CYBRD1 (accession no. NM_024843) crossed an exon-exon boundary,
Fig. 1. Reduction of ferricyanide (FIC) upon incubation with of Calu-3, H1299 and A549 cells, and metabolomics analysis of spent medium showing lactate change.
Cells with no increase of intracellular ascorbate levels used in the experiment.
(a) Typical linear sweep voltammograms of FIC (0.1 mM) reduction for (i) Calu-3, (ii) H1299, and (iii) A549 cells. Scanned from a 650 to −150mV, 10mV.s−1. (b)
Potassium ferrocyanide (FOC) production, on incubation with 0.1mM FIC, as a measure of FIC reduction by cells - without increased intracellular ascorbate; N=3,
n=3. Calu-3 and H1299 cells values significantly lower compared to A549 cells at P=0.0009 and P=0.0013, respectively. (c) Metabolomics analysis of spent
media of Calu-3, H1299 and A549 cells incubated with ferricyanide (FIC) in Hanks' Balanced Salt Solution (HBSS), relative to control cells in respective buffer only.
Changes in lactate metabolite are shown. False discovery rate (FDR) of< 0.05 for Calu-3 cells indicates significant difference.
Statistical analysis performed between cell types in figures (a) and (b) were made using two-way ANOVA with Tukey's multiple comparison test; p < 0.05 considered
statistically significant. For all comparisons: *p < 0.05, **p < 0.01, ***p < 0.001. N=3, n=3. All values represent mean from three biological replicates± SEM.
Figure (c) data was analysed via t-test using Metaboanalyst, with significance between samples said to be present if the false discovery rate (FDR) was<0.05. N=6,
n=1.
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and were of the following sequences: For. 5′ - TTGGACTGATAGCTGT
CATATGCT - 3′, Rev. 5′ - GAAATGCTCGGAGAGAAAGC- 3′.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primer pair was
provided by the David Heery laboratory (The Gene Regulation Group,
The University of Nottingham). Primer sequences for the GAPDH
housekeeping primer were: For. 5′ - AGGTGAAGGTCGGCGTCAA - 3′,
Rev. 5′ - GATGACAAGCTTCCCGTT- 3′. Relative quantification of
CYBRD1 gene expression by real-time PCR was performed according to
the manufacturer's protocol for the Brilliant II SYBR® Green QPCR
Master Mix (Agilent Technologies Ltd., #600828), using a Stratagene
Mx3005P thermocycler (Stratagene Ltd). This experiment was carried
out with twelve technical repeats and three biological repeats.
2.15. Flow cytometry for DCYTB knockdown
H1299 and A549 cells were seeded in 24 well plates at 5× 104 and
incubated for 24 h. The cells were transfected as described in the above
section. Cells were detached using 250 μL accutase per well. Once de-
tached, 250 μL of DMEM was added to each well to stop the action of
the accutase, and the cells were pelleted via centrifugation at 300 g for
5min. The resulting pellet was washed in PBS. The cells were then fixed
using 4% paraformaldehyde for 15min, prior to three subsequent wa-
shes with ice-cold PBS to remove any residual paraformaldehyde. The
samples were blocked/permeabilised for 5min using 1% PBA (PBS with
1% bovine serum albumin) and 0.1% tween-20. The cells were pelleting
via centrifugation (300 g, 5 min), before primary staining for 30min at
8 μg/mL in 1% PBA (ab66048, anti-cytochrome b reductase 1, Abcam
Ltd). A secondary only control sample was also set up for each plasmid
transfection, which was incubated with only 1% PBA/0.1% tween-20
(no antibody). Following staining, 1mL 1% PBA was added, and the
samples were centrifuged at 300g for 5min. The samples were then
secondary stained for 15min at 2 μg/mL, for all wells (Donkey anti-
Rabbit IgG (H+L) Highly Cross-Adsorbed, Alexa Fluor® 647, A31573,
ThermoFisher Scientific Ltd). Following completion of staining, 1mL
1% PBA/0.1% tween-20 was again added and the cells pelleted. The
samples were resuspended in 500 μL 1% PBA/0.1% tween-20 prior to
transportation to the flow cytometer on ice (FC500 Series Flow
Cytometer, Beckman Coulter Ltd). 25 μL 50 μg/mL propidium iodide
was added to one positive control sample, to ensure fixation and
permeabilisation had been effective. Laser lines for selected fluor-
ophores were as follows: AlexaFluor® 647: Beckman Coulter FC500,
633 laser line, emission 655–685 nm; green fluorescent protein (GFP):
Beckman Coulter FC500, 488 laser line, emission 514–542 nm; propi-
dium iodide: Beckman Coulter FC500, 488 laser line, emission
612–638 nm. Please note that examples of gating for flow cytometry are
displayed in Fig. S6c. This experiment was carried out with one tech-
nical repeats and four biological repeats.
2.16. Electrochemical analysis of transfected cells
H1299 and A549 cells were seeded in 6 well plates at 2.5× 105/
well, and transfected according to the above section. Following growth
period, each plasmid transfection (2× control plasmid, 2× shRNA1
plasmid and 2× shRNA2 plasmid) were incubated with HBSS only or
0.01mM potassium ferricyanide (FIC) in HBSS, for 2 h. The super-
natants were tested electrochemically, as outlined in the ‘electro-
chemical analysis’ section. This assay was repeated using the control
plasmid only, alongside non-transfected samples, to allow for accurate
comparison between non-transfected and transfected cell tPMET. This
experiment was carried out with one technical repeats and four biolo-
gical repeats.
2.17. Mitochondrial membrane potential upon transfection
H1299 and A549 cells were seeded in 96 well plates at 8.4× 104/
well in 150 μl DMEM, and transfected according the above protocol.
Upon completion of growth, the cells were incubated for 2 h with either
DMEM, negative control, 25 μM Carbonyl cyanide-4-phenylhydrazone
(FCCP, positive control), or HBSS. Each reagent was triplicated. This
was to simulate the two-hour HBSS/FIC incubation carried out for
electrochemical analysis. Mitochondrial membrane potential was as-
sessed using the JC-1 (5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetra-
ethylbenzimidazolylcarbocyanine, iodide) dye (Biotium, Inc.).
Preparation of the JC-1 reagent stock was as follows: 1mg/mL was
prepared dissolving 5mg JC-1 powder in 5mL DMSO, prior to vor-
texing to ensure homogeneity. The vial was left at room temperature for
~ 15min to ensure complete dissolution. Dissolved JC-1 stock was then
aliquoted out into 200 Eppendorfs of 25 μL each (provided at this
Fig. 2. Ascorbate's role in extracellular iron reduction; assessed in the presence of specific ascorbate oxidizing agent, ascorbate oxidase (AO).
(a) Potassium ferrocyanide ‘production’ attributed to extracellular ascorbate and non-extracellular ascorbate reduction of extracellular potassium ferricyanide (FIC),
for comparison between of extracellular ascorbate-mediated tPMET of the cell lines. Ferricyanide reduction attributable to extracellular ascorbate was significantly
different between both Calu-3 and A549 cells vs H1299 cells at P=0.0267 and 0.0007, respectively (b) Ascorbate ‘removal’; analysed voltammograms for presence
and absence of AO. AO+ wells were set up in parallel to AO- wells and the ascorbate attributable currents in each measured to provide the values presented in figure
b, a HBSS only (no cell incubation) current was subtracted as a baseline to obtain ascorbate release currents.
Statistical analysis performed using two-way ANOVA with Tukey's multiple comparison test; p < 0.05 considered statistically significant. All univariate comparisons
were made using one unpaired t-test per data set (cell type) with Holm-Sidak determination of significance; p < 0.05 considered statistically significant. For all
comparisons: *p < 0.05, **p < 0.01, ***p < 0.001. N=4, n=3. All values represent mean from three biological replicates± SEM.
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preparation). For the JC-1 assay, a 1× staining solution was prepared
by diluting 25 μL of 200× JC-1 stock in 5mL DMEM. This preparation
was then vortexed and incubated at room temperature for 1–2min.
50 μL of 1× JC-1 staining solution was added to each well, and in-
cubated for 15min. Following this incubation, the reagent was removed
and the cells were washed with 50 μL PBS per well. The fluorescence
was then measured using a Tecan Microplate Reader (Tecan Ltd.,
Weymouth, UK). Fluorescence of JC-1 aggregates (red) was measured at
λex. 550 nm/λem. 600 nm, and green fluorescence of JC-1 monomers
measured at λex. 485 nm/λem. 535 nm. The ratio of red/green fluores-
cence was determined, with a higher ratio indicating more intact mi-
tochondrial membrane activity. This experiment was carried out with
three technical repeats and four biological repeats.
2.18. Cellular redox activity and membrane perturbation upon transfection
H1299 and A549 cells were seeded and transfected in 96 well plates
according to the above protocols. The cells were incubated for two
hours with HBSS to simulate electrochemical assay conditions. The MTS
assay and lactate dehydrogenase (LDH) assays were then performed on
the same samples to determine cellular metabolic activity and mem-
brane perturbation, respectively. The protocols for these assays, fol-
lowing reagent incubation, are as outlined previously [61]. These ex-
periments were carried out with three technical repeats and four
biological repeats.
Fig. 3. Duodenal cytochrome b (Dcytb) immunostaining of (a) Calu-3, (b) H1299 and (c) A549 cells.
Focus stack images are shown as 3D rendered images (i and ii) or in orthogonal views (iii) and permeabilised cells iv). Antibody combinations were as followed: (i)
Secondary antibody only, 2 μg/mL Alexa 647. (ii) Primary antibody (ab66048) 10 μg/mL, and secondary antibody, 2 μg/mL Alexa 647. (d) Flow cytometry for Dcytb
in non-transfected Calu-3, H1299 and A549 cells.
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2.19. Statistical analysis
All statistical analysis was performed using GraphPad Prism 7.01,
whereby p < 0.05 was considered statistically significant. Appropriate
statistical tests were chosen depending on the requirement for one and
two factor analysis of variance, with appropriate ad hoc hypothesis
tests.
3. Results
3.1. Linear sweep voltammetry as a method to study tPMET
We recently developed and applied a new electrochemical based
assay, using linear sweep voltammetry, to identify different external
electron flux rates. This assay was applied to A549, Calu-3 and H129
cells, and these cell types were also used in the current study [61]. The
assay quantitates the electrical charge which is transferred across the
plasma membrane via an iron redox reporter molecule, as described in
the supporting information (Fig. S1). The important component of the
graphs Fig. 1a which represents the magnitude of the external charge
flux by the cells is the steady state current observed at approximately
0.3 V. The value of this is proportional to the number of FIC molecules
reduced by the cell to FOC. The FOC is then electrochemically oxidised
yielding a steady state anodic current which is measured and plotted in
Fig. 1 b. Fig. 1 therefore shows reduction capacity of tested cells, in-
dicating similar levels for Calu-3 and H1299 cells and significantly
higher level for A549.
The data further show that the presence of higher concentration of
FIC - the redox state of iron known to affect cellular metabolism - has an
effect on lactate metabolism of Calu-3, whilst for H1299 and A549 cells
there was no detectable change in the metabolism of lactate upon FIC
incubation (Fig. 1c). Lactate was selected as marker because its meta-
bolism is implicated in regenerating NAD+ levels in cancer [68]. This
draws a parallel to the use of NADH by tPMETSs for the regeneration of
NAD+. This is noteworthy as it may suggests that the upregulation of
lactate metabolism may work in tandem with higher tPMET activity in
Calu-3 cells, implying a link between energy reprogramming and
tPMETs which is an essential trait of cancer.
Here we first apply linear sweep voltammetry to investigate tPMET
activity in selected cell lines. We hypothesised that two routes of trans-
Fig. 4. Duodenal cytochrome b (Dcytb) involvement in trans plasma membrane electron transport.
(a and b) Flow cytometry for Dcytb protein when cells were transfected with control and knockdown plasmids; (a) H1299, (b) A549 (representative histograms
obtained which were used to construct these bar charts can be seen in Fig. S7). N=4, n=1. A549 cells showed a significant reduction in Dcytb protein expression at
P=0.006 and 0.001 for shRNA 1 and shRNA 2 vs control, respectively. H1299 cells showed no significant change. (c and d) Electrochemical analysis of the reduction
of 0.01mM potassium ferricyanide (FIC) by cells transfected with control or knockdown plasmids; N= 4, n= 1; (c) H1299, (d) A549. A549 cells showed a significant
reduction in tPMET activity (i.e. FOC production) at P=0.028 and 0.013, shRNA1 and shRNA2 vs control, respectively. H1299 cells showed no significant change.
Statistical analysis performed using one-way ANOVA with Tukey's multiple comparison test; p < 0.05 considered statistically significant. For all comparisons:
*p < 0.05, **p < 0.01, ***p < 0.001. All values represent mean from three biological replicates± SEM.
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plasma membrane electron transport in cancer cells could occur; one via
direct electron transfer using DcytB, and second occurring by a medi-
ated process involving ascorbate.
3.2. Ascorbate efflux as a trans plasma membrane electron transport system
(tPMETS)
To confirm that ascorbate plays a role in shuttling electrons leading
to FIC reduction into FOC (Fig. 1), cells were incubated with the
ascorbate-specific oxidising agent, ascorbate oxidase (AO) in the and
presence of FIC (Fig. 2a) and its absence (Fig. 2b). The AO removed
ascorbate from the medium. Electrochemical analysis and assessment of
the magnitude of the anodic current at approximately 0.3 V was per-
formed in the presence and absence of AO with FIC (Fig. 2a). Conse-
quently, any differences observed in oxidative currents associated with
FOC oxidation could be attributed to the reduction of FIC to FOC by
ascorbic acid. This therefore allows for tPMET activity to be calculated
and attributable to extracellular ascorbate. To conduct the study, a
Fig. 5. (a-h) Trans plasma membrane electron transport is upregulated in response to mitochondrial stress.
(a and b) Electrochemical analysis of cellular reduction of 0.01mM potassium ferricyanide into ferrocyanide in cells transfected with control plasmid and non-
transfected counterparts; N=4, n=1. Increases in tPMET activity following transfection were observed for both H1299 and A549 cells (H1299, P=0.0229; A549,
P=0.0304). (c and f) JC-1 assay for mitochondrial membrane potential; N= 4, n=3. No significant difference was found between FCCP incubated cells and
transfected cells, with significant differences compared to a non-transfected control of P=0.002, 0.003 and 0.034 or H1299 (Fig. 5c) control, shRNA1 and shRNA2
plasmids, respectively. For A549 cells (Fig. 5f) a similar trend was observed with control and shRNA1 plasmids showing a significant decline compared to non-
transfected cells of P=0.009 and 0.004, respectively; (d and g) MTS assay for cellular metabolic activity; N=4, n=3; No significant reductions in MTS activity
were observed compared to a non-transfected control besides for the knockdown plasmids of H1299 cells (shRNA1, P=0.033; shRNA2, P=0.011). (e and h) Lactate
dehydrogenase (LDH) assay; N= 4, n=3; No significant changes for all samples were observed (f-h) Statistical analysis performed using one-way ANOVA with
Tukey's multiple comparison test; p < 0.05 considered statistically significant. Univariate comparisons (a and b) were made using unpaired t-test p < 0.05 con-
sidered statistically significant. For all comparisons: *p < 0.05, **p < 0.01, ***p < 0.001. All values represent mean from three biological replicates± SEM.
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signal (current) amplification associated with FIC reductions (voltam-
mogram Fig. S1) was achieved by loading of the cells with DHA which
was transported into the cell using GLUT transporters (Fig. S2) and
converted to ascorbic acid (Fig. S3). The data in Fig. 2 illustrate that all
cell lines tested employ effluxed extracellular ascorbate to reduce ex-
tracellular FIC, but differ in their proficiency to do this.
Regarding Calu-3 and A549 cells, the FIC reduction attributable to
extracellular ascorbate was no different between the cell lines, with
values of 15.6% and 20.9%, respectively (Fig. 2a). The FIC reduction
attributable to extracellular ascorbate was significantly different be-
tween Calu-3 and A549 cells versus H1299 cells, with the significantly
lower portion of extracellular ascorbate-mediated tPMET at 6.7% for
H1299 cells (Fig. 2a). Fig. 2b shows data obtained for cells treated with
ascorbate oxidase in the absence of FIC. This confirms that the differ-
ence observed in Fig. 2a is attributable to ascorbate efflux. It should be
noted that the data in Fig. S4 and S5 confirm that the efflux of ascorbate
in all three cell types tested occurs via anion channels, inhibited by
glucose transport inhibitors (DIDS and SITS), whereby in Calu-3 cells
the data also point to the involvement of volume-sensitive anion
channels (VSAC).
An interesting observation is that the tPMET activity increases sig-
nificantly upon ascorbate supplementation. When ‘loaded’ with ascor-
bate via DHA incubation, the tPMET activity, as measured by FIC pro-
duction, was 129, 141 and 171 nM FOC per μg of protein for Calu-3,
H1299 and A549 cells, respectively. Compared to the basal tPMET level
(Fig. 1) this represents a 21.5, 22.7 and 17.4 fold change in FOC pro-
duced per μg of protein for Calu-3, H1299 and A549 cells upon in-
creasing intracellular ascorbate.
3.3. Duodenal cytochrome b (Dcytb) role as a direct electron tPMET
The images and flow cytometry data in Fig. 3 show live-cell im-
munostaining, which demonstrates the presence of Dcytb in the cancer
cell lines tested. The images depict Dcytb protein staining (in red)
forming a ‘halo’ at a distance from the cell nuclei (in blue) in non-
permeabilised cells. The orthogonal images in Fig. 3iii, relative to Fig. 3
iv confirm this location of the staining. As the immunostaining proce-
dure was conducted on ice, with no permeabilisation or fixation of the
cells, the experiment would hence indicate the presence of Dcytb at the
plasma membrane of the cells. The location of Dcytb is important in the
context of its role in tPMET as, by definition, tPMET must occur through
the transfer of electron across the plasma membrane.
3.4. Dcytb acts as tPMET syste in A549 cells
To determine the role of Dcytb in tPMET, we transfected cells with
shRNA-expressing plasmids (shRNA1 and shRNA2) to knockdown the
Dcytb-encoding gene CYBRD1. Transfection data show (Fig. S6a) sig-
nificant differences in efficacy, with very low levels obtained for Calu-3
cells with both plasmids. In H1299 cells a significant knockdown of
CYBRD1was achieved with the shRNA1 plasmid, and in A549 cells with
both shRNA1 and shRNA2 plasmids (Fig. S6b). At the protein level, data
show no significant knockdown of Dcytb protein expression for H1299
cells, but a significant difference for both knockdown plasmids in A549
cells, compared to the control (Fig. 4a and b).
Electrochemical assays made comparisons between transfected
H1299 and A549 cell lines, as the cells with the least and the most
proficient ascorbate shuttling mechanisms (as per Fig. 2a). No statisti-
cally significant reduction in tPMET activity was observed for H1299
cells upon Dcytb knockdown, relative to control plasmid transfected
cells (Fig. 4c and d), which would be expected as per absence of
knockdown effect at the protein level (Fig. 4a and b). A significant
reduction in FOC production in A549 cells (Fig. 4d) suggests a promi-
nent role for Dcytb in tPMET activity. Since no change in Dcytb protein
level was observed for H1299 cells, we cannot conclude that Dcytb acts
as a tPMET in this cell line. However, the presence of Dcytb confirmed
by immunostaining suggests this is likely possible.
Fig. 6. Summary of findings. tPMET may occur using Dcytb or ascorbate shuttling, and this varies between the cells. tPMET enzymes/transporters: DCYTB (duodenal
cytochrome b561), GLUT (glucose transporter). Redox co-factors: AscH (ascorbate monoanion), AFR (ascorbate free radical), DHA (dehydroascorbate), [Fe(CN)6]3−/
[Fe(CN)6]3− (ferricyanide/ferrocyanide (reduced/oxidised), O, oxidised redox co-factor, R, reduced redox co-factor (where R/O can include NADH/NAD+ (nico-
tinamide adenine dinucleotide (reduced/oxidised)), NADPH/NADP+ (nicotinamide adenine dinucleotide phosphate (reduced/oxidised)), GSH/GSSG (glutathione/
glutathione disulphide (reduced/oxidised)).
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3.5. Trans plasma membrane electron transport is upregulated in response
to mitochondrial stress
We should point out to an interesting side observation seen for cells
transfected with the control plasmid. Data in Fig. 4 show an upregu-
lation of tPMET activity in H1299 (Fig. 4c, control plasmid) and A549
(Fig. 4d, control plasmid) transfected cells, compared to the basal levels
in the range of 2 and 5 nM/μg protein seen using the same FIC con-
centration, respectively observed under same experimental conditions
in our previous published study using 0.01mM of FIC [61]. A com-
parison to Fig. 1 was not made as a higher FIC concentration was used
which can alter the tPMET activity. A lower concentration of 0.01mM
was used to maximise our signal to noise ratio. To investigate this
further, biochemical assays were conducted to elucidate if a link be-
tween cellular stress, due to transfection process, and tPMET activity
may exist in H1299 and A549 cells (Fig. 5).
Fig. 5a and b compare FOC production in non-transfected, control
cells and cells transfected with the control plasmid. The data clearly
indicate a significant difference in FOC production, i.e. oxido-reductive
capacity of the cells, with a clear increase for the transfected counter-
parts. The analysis of mitochondrial membrane potential, shows a sig-
nificant reduction in transfected A549 and H1299 cells, comparable in
extent to carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP), a compound which causes depolarisation of the mitochondrial
membrane (Fig. 5c and f). MTS assay data on cellular metabolic activity
of transfected cells showed some reduction (Fig. 5d and g), where it
should be noticed that MTS assay reflects activity of NAD(P)H-depen-
dent oxidoreductase enzymes which are present mainly in the cell cy-
tosol [69] and the data would hence indicate that despite a dramatic
decrease in mitochondrial membrane potential, cellular metabolic ac-
tivity was largely maintained. Lactate dehydrogenase (LDH) assays
showed no significant difference compared to the non-transfected
control, indicating no necrotic process occurring (Fig. 5e and h). We
would thus tentatively suggest that the results indicate that the activity
of tPMET is upregulated when the cell experiences mitochondrial stress,
and that this may play role in maintaining cellular redox capability
[7,17].
4. Discussion
In this study we have investigated two mechanisms by which elec-
trons are transported across the cell cytoplasmic membrane from three
lung cancer cell models. The aim of the study was to establish what
tPMET systems cells use to inform on their role in bioenergetics. One
mechanism was found to occur via an ascorbate-mediated tPMET
system and contributes differently to the overall oxido-reductive ca-
pacity of the cells with 20.9% for A549, 6.7% for H12199, and 15.5%
for Calu-3 cells. The data confirmed that ascorbate is transported via an
anion transporter across the plasma membrane in all three cell lines,
whereby Calu-3 cells may also employ a volume-sensitive anion
channel (Figure S4). Once transported outside of the cells, ascorbate
then passes an electron on to FIC present in the medium (Fig. 6), as
proven by cell treatment with ascorbate oxidase; the enzyme reduced
the ascorbate mediated electrochemical signal to effectively zero. Our
results however contrast the data in non-malignant bronchial epithelial
cells, whereby ascorbate supplementation did not increase iron uptake
[9], although it should be noted that the study did not measure tPMET
activity directly as in our study, rather cellular iron conctrations.
Moreover, it has been suggested that the reducing equivalent for Dcytb
intracellularly is ascorbate [70], although quercetin has also been
proposed as an electron sink [71].
The second mechanism we identified contributing to transmem-
brane electron transport is the ferrireductase duodenal cytochrome b
(Dcytb). All tested cell lines express Dcytb protein, as confirmed by
immunostaining. Successful knockdown of Dcytb gene in A549 cells
conforms its role as a tPMET in this cell type, however we could not
established its role in other tested cells as per unsuccessful knockdown.
Overall, the way the cells use these tPMET systems differs between
them, as evidently seen for ascorbate transport. The key importance of
our work is to realise the heterogeneity in the use of these systems by
different cell types and its importance for drug discovery of molecules
that target these systems for e.g. cancer therapy [71,72]. For instance, if
one were to target ascorbate-shuttle based tPMET in H1299 cells it
would be a less successful approach compared to A549 and Calu-3 cell
types.
The latter part of our study has drawn a link between depolarisation
of mitochondrial membrane potential in transfected cells and an in-
crease in plasma membrane charge transfer. Other studies also observed
similar higher tPMET levels when mitochondria are dysfunctional
[7,17,23,73].
The current studies in the field are focusing on deciphering how
more than one energy metabolism mechanism may exist in malignant
tumour cells – the Warburg effect [18,19,43,44,75–77] and the reverse
Warburg effect may be occurring [78–80]. The reverse Warburg effect
has been described, in which cancer cells use reactive oxygen species
(ROS) to induce the Warburg effect in cancer-associated fibroblasts
(CAF), and then utilise the cell-exported lactate and pyruvate metabo-
lites to increase the rate of oxidative phosphorylation. There is evidence
in vivo that in some lung tumours a switch from oxidative to glycolytic
metabolism does not occur, the latter would be predicted by the War-
burg effect [81]. It is also noted that there is a high degree of metabolic
heterogeneity between different tumours (all non-small cell lung can-
cers with varying histology) and between similar tumour types, so the
hypothesis that tPMET may be targeted to induce anti-proliferative
effects in malignant cells is still valid. There is also mounting evidence
that targeting mitochondrial metabolism in cancer may be viable route
of therapy [82], and its use in tandem with the targeting of tPMET may
prove useful in future drug discovery. Our data suggest that to target
therapy against tPMET systems it is of paramount importance to un-
derstand tPMET heterogeneity in difference cell types and cancers.
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